WASHINGTON (March 7, 2016) — America’s biopharmaceutical research companies are working to advance the treatment of osteoporosis with nine medicines in development, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Osteoporosis Foundation (NOF).
Nearly 54 million Americans live with osteoporosis or low bone density, and that number is expected to reach more than 71 million by 2030. What’s more, half of women and a quarter of men over the age of 50 are expected to break a bone as a result of osteoporosis. New treatments and innovations in development by biopharmaceutical companies are providing hope for these Americans and their families.
“We are pleased to see that there continues to be progress made in the development of treatments for osteoporosis, but as our aging population continues to grow, there is more work to be done for patients,” said Stephen J. Ubl, president and chief executive officer of PhRMA. “With 3 million bone fractures expected a year by 2025, biopharmaceutical companies are committed to advancing osteoporosis research and discovering new treatment options to help patients live longer, healthier lives.”
The new report, “Medicines in Development for Osteoporosis,” highlights that all nine medicines currently in development are either in clinical trials or undergoing regulatory review by the Food and Drug Administration. There are also 34 clinical trials ongoing across the United States studying osteoporosis treatments.
The medicines in development use novel approaches to treating the disease and include:
- 5 medicines for postmenopausal osteoporosis
- 2 medicines specifically for men with osteoporosis
- 2 medicines for drug-induced osteoporosis
Equally as important as the development of medicines are fracture prevention efforts to help older Americans with osteoporosis or low bone mass. NOF continues to lead such efforts, including its Fracture Prevention Initiative aimed at providing training, tools and resources for health care professionals to support the implementation of Fracture Liaison Service care coordination programs.
“We are encouraged by advancements in the research and development of treatments for osteoporosis,” said Robert F. Gagel, M.D., president of NOF. “New treatments and prevention efforts provide hope for a future in which fewer Americans suffer from the pain and disability this disease causes.”
View the full report here: http://phrma.org/sites/default/files/pdf/medicines-in-development-report-osteoporosis.pdf.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.